Attivare Therapeutics

Attivare is a biopharmaceutical company advancing a differentiated modular vaccine platform based on immuno-material technology developed at the Wyss Institute. Attivare’s technology, when injected into the body, forms a porous scaffold made up of mesoporous silica rods (“MSP”) loaded released immune cell recruiting factors which promote recruitment of dendritic immune cells. The Company’s platform has potential applications across a wide variety of therapeutic areas, from bacterial and viral infections to oncology, where the platform can improve the robustness and duration of immune response by attracting and concentrating large numbers of immune cells.